You are here

migraines

After culling workforce, migraine biotech Zosano drops lead — and sole — program

Endpoints

Mon, 05/2/22 - 11:00 am

Biohaven migraine drug partnered with Pfizer lands twin European approvals

MedCity News

Wed, 04/27/22 - 10:38 pm

Axsome expects migraine drug to be rejected as manufacturing issues arise

Endpoints

Mon, 04/25/22 - 10:42 am

Axsome Therapeutics

Zosano's headaches continue: Biotech lays off 31% after FDA rejects migraine drug resubmission

Fierce Biotech

Thu, 03/17/22 - 11:16 pm

AbbVie touts Qulipta chronic migraine win as Biohaven duel heats up

Fierce Pharma

Thu, 03/10/22 - 10:22 pm

Tiny pharma hits a new low with FDA refusing to review company's response to its CRL

Endpoints

Tue, 02/22/22 - 10:57 am

complete response letter

AbbVie runs first Qulipta TV ad spots as it focuses on what you ‘can control inside’

Fierce Pharma

Fri, 02/11/22 - 11:46 am

pharma marketing

AbbVie’s Qulipta gains ground with docs for migraine prevention, as pharma looks to pressure Biohaven’s Nurtec

Fierce Pharma

Thu, 02/10/22 - 08:02 pm

Novartis, Amgen settle their dueling lawsuits over migraine drug Aimovig

Fierce Pharma

Tue, 02/1/22 - 11:28 pm

Pfizer and Biohaven close collaboration agreements

Pharmaceutical Business Review

Thu, 01/6/22 - 10:54 am

Biohaven pain spray aces test as C-suite shake-up sees incoming CFO, chief in chairman role

Fierce Biotech

Mon, 12/6/21 - 10:50 am

Tonix Cleared to Propel Migraine Therapy into Phase II

BioSpace

Tue, 11/23/21 - 08:52 pm

Tonix Pharmaceuticals

clinical trials

Amgen, Biohaven, Lilly and Teva plowed plenty into marketing migraine meds. Is it working?

Fierce Pharma

Mon, 11/22/21 - 10:21 am

pharma marketing

Teva Pharmaceutical

Eli Lilly, under pressure from Biohaven, launches head-to-head migraine trial between Emgality and Nurtec

Fierce Pharma

Thu, 11/18/21 - 11:03 pm

clinical trials

Amid crowded migraine market, Lundbeck goes its own way

Pharmaforum

Mon, 11/15/21 - 10:42 am

Citing migraine drug growth and pandemic, Lundbeck to cut 300 jobs and close India facility

Endpoints

Fri, 11/12/21 - 10:39 am

Biohaven, Pfizer enter up to $1.24 bln deal to market migraine drugs

Yahoo/Reuters

Tue, 11/9/21 - 10:38 am

Buckle up AbbVie, Amgen: Biohaven's oral CGRP drug is gaining traction in migraine, doctors’ survey shows

Fierce Pharma

Fri, 10/22/21 - 12:42 pm

Biohaven migraine drug sales again top Wall Street forecasts

BioPharma Dive

Wed, 10/6/21 - 11:20 pm

AbbVie’s Qulipta Set to Become Blockbuster in the Migraine Market

Clinical Trials Arena

Sun, 10/3/21 - 08:11 pm

Pages